Symbiotec Pharmalab Limited (SYMBIOTEC)
Outcome of Board Meeting
FY2026 results (audited):
Standalone:
Revenue 8.5bn +4% y-y (8.45bn)
EBITDA 2.3bn +2% y-y (2.34bn)
EBITDA margin 27.7% (27.8%) -10 bps y-y
PAT 1.2bn +5% y-y (1.16bn)
Consolidated:
Revenue 8.7bn +8% y-y (8.69bn)
EBITDA 2.3bn +2% y-y (2.34bn)
EBITDA margin 26.5% (27.0%) -50 bps y-y
PAT 1.1bn +10% y-y (1.10bn)
Dividend: Not declared
Commentary: Exceptional item for FY2026 relates to impact of new wage code on gratuity and leave encashment expense of 89.93 million.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 SYMBIOTEC — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add SYMBIOTEC to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Symbiotec Pharmalab Limited
Important.
The summary above is generated automatically from Symbiotec Pharmalab Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.